Member Info for Thelix

It's neutral/good news hence the price has stayed the same. Its great they have contracted expertise but it doesnt speed up nasdaq or advance it in any way. Still, nice to know they have an experienced team helping them.

Haha. FDA recognise genetic/geographical differences and that drugs do have different effectiveness on certain populations. Certain genetic subtypes have better reception to drugs with certain target receptors. FDA put the 50% requirement on companies to ensure it works in US people. A very interesting subject - just a google away. It's how they made a superior product to help black peoples heart health as they naturally have higher nitrogen in their blood vessels which raises blood pressure.

So small digestion. Looks good - just a shame it isnt a stateside clinical company. The bit I like is the merging of regulatory and quality assurance - it means this will pretty much be ready to go when the data is audited by FDA etc. Sounds dull and is a red tape step, but without it you cannot progress. Easiest way small pharma fails is not properly following reg guidelines etc so with expert help this should whip everything into shape and once that phase 2 data is out and passes (which it should - our p values were tiny!) it should be easy to go to phase 3. USA enforces that any product sold in US has to have a phase 3 clinical trial in their country with minimum 50% US people. I hope VRP knows this because so far the trials have been British - kind of why I was hoping for a stateside clinical group

I am happy with daily 5-7% rises. No need for spikes, hopefully this gets another 5-7% today which should see us in 3.3p territory.

Interesting....Need to digest that one.

did a quick post check - what a troll.

ethical 20 million Americans suffer from GI irritation, and cannot take many NSAID's. Even if only half that affected population use this, only 3 times a year, and its $1 per time, that is $30 mil, aka the mcap of this company. The reality is this will make revenue of a few hundred million $ a year easily at commercial scale. GWP was worth £2.5 billion and isnt even commercial yet!. I think you seriously underestimate how much pharma is worth. 50p options is an mcap of £650 million which is very low for pharma. Now, this is obviously near/at commercialisation. However 20p ( £150 mil ) on approval and commercial partnerships being formed isnt that crazy. This was at 13p pre dilution at an mcap of 170 mil 2 years ago on the hope of finding a comm partner. Please take your mining stock mentality and leave if you dont know the basics of pharma mcap capabilities.

On the nose from the spread so...difficult to tell.

This should pass 8p in a flash quite frankly lol. If FDA news is good and commercial partner is found this will go ballistic.

I am thankfully surprised this is sitting at 144p. If it sits here or goes a little higher then will be a non painful nasdaq launch

it went from 3p to 13p.

Every buy pretty much causes a tick up followed by a sell just .01 below the share price. Something is going on, even for OXP which moves on small volume this is insane.

of 3.3p just hit. Hope those who got in at 3.6p a month ago held their nerve - this is going to be a very high blue day it seems. I am wondering if this flurry of buying is due to news coming very soon or if results are known to some...

on the basis of getting commercial partners. If FDA response goes well and they get a commercial partner I see no reason why this would be less than 13p. I would expect the 20p options to be hit. 50p would be hit once revenue starts coming in. But theres a reason the directors were given options at 50p - it is achievable. Its an Mcap of £650 million to get to 50p. £650 mil for pharma in commercial sales is low/medium mcap. Depends how long you want to wait.

About to smash through 3p. Hoping today sees another 5% + rise.

afternoon than expected, but heading in same direction. Not many trading days left until expected FDA response.

and ask moving higher with each buy. 3p just gone through. Even if only Rx is going forward this will make revenue of hundreds of millions per annum. There are millions who cannot take NSAIDs due to GI issues, even under prescription this will sell like hotcakes and its a proven compound so this is closer to commercialisation than people think!

OTC is a maybe, Rx is pretty much guaranteed in my opinion. To those who read my analysis a few weeks back (those 3 huge posts) I stated why I thought OXP would struggle with OTC route and the latest RNS mirrors this. OXP mention nurofen a LOT. The makers of Nurofen got in trouble for basically advertising multiple products for multiple pains (periods, headache, toothache etc) and priced it differently despite the fact it was the same product - Ibuprofen. I think the commercial partners said to OTC this you need to prove this product is different. Now, we know it differs as it stops GI irritation - but you cant OTC diagnose that and people would buy OXP products despite not having GI irritation. I believe this is why the last RNS stated it had same bioequivalence as nurofen but also had added properties - to make it a capable OTC drug. In my educated opinion within pharma Rx (Prescription) is almost guaranteed. OTC would be amazing and rerate this insanely high. That said, its at £30m mcap. Rx will see this bag multiple times. OTC double it. DYOR etc

Won't be until Monday mate. Always delay on the Friday. Here's hoping we get a stonker - but just a hunch about Friday/Monday. Officially still have over 5 trading days before Q1 ends.

will last 9 weeks per patient as and when they are recruited. So it isn't a task of finding n=x people and doing a big 9 week block on everyone. You just start treatment when they arrive and after 9 weeks store the data into a safe depository as it is a blind controlled study and when you have n=x completed you get the data back out, pool it, crunch it, and hope its below 0.05 p value. Obviously I have simplified it but yeah thats roughly how it works.